Suppr超能文献

钙通道阻滞剂的副作用。

Side effects of calcium channel blockers.

作者信息

Russell R P

机构信息

Renal Division, Good Samaritan Hospital, Baltimore, MD 21239.

出版信息

Hypertension. 1988 Mar;11(3 Pt 2):II42-4. doi: 10.1161/01.hyp.11.3_pt_2.ii42.

Abstract

Calcium channel blocking drugs are a chemically heterogenous group, so it might be expected that their effects on vascular smooth muscle, cardiac contractility, and conduction tissue may differ. However, the majority of adverse reactions are predictable from their pharmacological actions and may be conveniently grouped in the following categories: 1) vasodilatation, 2) negative inotropic effects, 3) conduction disturbances, 4) gastrointestinal effects, 5) metabolic effects, and 6) drug interactions. Vasodilatory symptoms, namely, dizziness, headaches, flushing sensation, and palpitation, are more likely with nifedipine. Peripheral edema is also common with nifedipine, but the mechanism is uncertain. For a given degree of vasodilation, the greatest negative inotropic effect is seen with verapamil first, diltiazem second, and nifedipine last. Calcium channel blocking drugs are contraindicated in hypertensive patients with second and third degree heart block, sick sinus syndrome, and severe heart failure. Verapamil and diltiazem have a significant effect on cardiac conduction, whereas nifedipine, in therapeutic doses, does not. Local gastrointestinal symptoms, such as nausea and constipation, are common with verapamil. None of the calcium channel blocking drugs have been reported to adversely affect lipid or protein metabolism. However, nifedipine, verapamil, and diltiazem in high doses may inhibit liberation of insulin. The significance of this finding needs to be explored further in hypertensive diabetics. Serum digoxin levels have been shown to increase after administration of verapamil and nifedipine, but there is no evidence that this change has any clinical relevance.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

钙通道阻滞剂是一类化学结构各异的药物,因此可以预期它们对血管平滑肌、心肌收缩力和传导组织的作用可能有所不同。然而,大多数不良反应可从其药理作用预测,并可方便地分为以下几类:1)血管舒张;2)负性肌力作用;3)传导紊乱;4)胃肠道作用;5)代谢作用;6)药物相互作用。硝苯地平更易出现血管舒张症状,即头晕、头痛、面部潮红和心悸。硝苯地平也常出现外周水肿,但其机制尚不清楚。对于给定程度的血管舒张,维拉帕米的负性肌力作用最强,其次是地尔硫䓬,硝苯地平最弱。钙通道阻滞剂禁用于二度和三度心脏传导阻滞、病态窦房结综合征和严重心力衰竭的高血压患者。维拉帕米和地尔硫䓬对心脏传导有显著影响,而治疗剂量的硝苯地平则无此作用。维拉帕米常出现局部胃肠道症状,如恶心和便秘。尚无报道称任何一种钙通道阻滞剂会对脂质或蛋白质代谢产生不利影响。然而,大剂量的硝苯地平、维拉帕米和地尔硫䓬可能会抑制胰岛素的释放。这一发现的意义在高血压糖尿病患者中需要进一步探讨。服用维拉帕米和硝苯地平后,血清地高辛水平已显示升高,但没有证据表明这种变化具有任何临床相关性。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验